Posted by Michael Wonder on 31 Aug 2020
VelosBio announces FDA fast track and orphan drug designations for VLS-101 in patients with mantle cell lymphoma
31 August 2020 - VelosBio today announced that the U.S. FDA has granted the company fast track and orphan drug designation for VLS-101 for the treatment of patients with mantle cell lymphoma.
VLS-101 is a ROR1-directed antibody-drug conjugate that is currently being studied in a first-in-human Phase 1 clinical trial in patients with relapsed or refractory haematologic cancers.
